Arcus Biosciences, Inc. - RCUS STOCK NEWS

Arcus Biosciences, Inc. (NYSE: RCUS) announced participation in a fireside chat at the Evercore ISI HealthCONx 2021 Conference on December 1, 2021, at 4:20 p.m. ET. A live audio webcast will be accessible through the company's website, with a replay available for two weeks post-event. Founded in 2015, Arcus is focused on developing novel therapies for cancer, with six investigational medicines in clinical studies targeting various pathways, including TIGIT and PD-1. For more details on their programs, visit www.arcusbio.com.

Gilead Sciences has exercised options for three clinical-stage programs from Arcus Biosciences, including anti-TIGIT agents domvanalimab and AB308, as well as etrumadenant and quemliclustat. This move involves $725 million in option payments to Arcus. The companies are set to co-develop these candidates, share global costs, and explore innovative treatment combinations. Antitrust clearance is required, with expected closure by year-end.

Gilead Sciences has exercised options for three clinical-stage programs from Arcus Biosciences, including domvanalimab, AB308, etrumadenant, and quemliclustat. The agreement, subject to antitrust clearance, results in Arcus receiving $725 million in option payments. The collaboration aims to accelerate the clinical development of these programs, which target hard-to-treat cancers like lung and pancreatic cancer. Notably, Gilead will pursue novel treatment combinations, enhancing its oncology portfolio.

Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of stock options to a new employee, totaling 28,000 shares at a price of $34.74 each, reflecting the closing price as of November 8, 2021. This issuance is part of the company's 2020 Inducement Plan, approved by the Board of Directors in January 2020. The company focuses on developing cancer therapies, with six investigational drugs currently in clinical studies targeting well-characterized biology and pathways.

Arcus Biosciences (RCUS) reported Q3 2021 results, showing a net loss of $78 million, a significant decline from net income of $1.8 million in Q3 2020. Collaboration revenues dropped to $9.5 million vs. $64.5 million year-over-year. Cash and investments rose to $743 million, providing funding through at least 2023. Gilead is reviewing an opt-in for Arcus's anti-TIGIT program, potentially yielding a $275 million payment. The ARC-7 study showed superior efficacy for domvanalimab combinations in non-small cell lung cancer. However, R&D expenses surged, raising concerns about financial sustainability.

Arcus Biosciences, Inc. (NYSE:RCUS) announced it will report its financial results and corporate update for Q3 2021 on November 8, 2021, after market close. The company focuses on developing innovative molecules and combination therapies for cancer treatment, working on five investigational medicines targeting pathways like TIGIT and PD-1. Founded in 2015, Arcus aims to expedite the development of first or best-in-class cancer therapies through collaboration with industry partners, patients, and physicians.

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company, announced the grant of stock options to six new employees. These options total 48,800 shares at an exercise price of $34.38, based on the closing price from October 25, 2021. The stock options were issued under the 2020 Inducement Plan approved by the Board of Directors in January 2020. The company continues to develop innovative cancer therapies, with five molecules currently in clinical development targeting significant unmet needs in oncology.

Arcus Biosciences (NYSE:RCUS) has granted stock options to eight new employees, totaling 66,400 shares at an exercise price of $31.48 per share, reflecting the closing price on October 8, 2021. This grant was made under the Company's 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing cancer therapies, with five molecules currently in clinical trials, including Etrumadenant and Quemliclustat, addressing various cancer types. The company aims to meet significant unmet medical needs in oncology.

Arcus Biosciences (NYSE:RCUS) announced the granting of stock options to eight new employees, allowing them to purchase a total of 58,200 shares at $36.99 each, the closing price on September 23, 2021. This action is part of the 2020 Inducement Plan approved by the Board. The company is focused on oncology and has five clinical molecules in development, including Etrumadenant, Quemliclustat, and Domvanalimab, targeting various cancers with innovative therapies.